The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1259
April 23, 2007
View Complete Issue         Table of Contents 2019 
Panitumumab (Vectibix) for Metastatic Colorectal Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Panitumumab (Vectibix) for Metastatic Colorectal Cancer
April 23, 2007 (Issue: 1259)
Panitumumab (Vectibix - Amgen), a fully human IgG2 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), has been approved by the FDA for treatment of patients with EGFR-expressing metastatic colorectal cancer that has...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Panitumumab (Vectibix) for Metastatic Colorectal Cancer
Article code: 1259b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.